Crescent Biopharma Inc
F:C68
Crescent Biopharma Inc
F:C68
Price:
15.4
EUR
-4.35%
Market Closed
Market Cap:
€213.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Crescent Biopharma Inc
F:C68
|
US |
|
N
|
North American Construction Group Ltd
F:N5Z
|
CA |
|
Eastone Century Technology Co Ltd
SZSE:300310
|
CN |
|
O
|
Ocean Bio-Chem Inc
F:OBC
|
US |
|
G
|
General Dynamics Corp
XBER:GDX
|
US |
|
Mitsubishi Electric Corp
TSE:6503
|
JP |
|
Apple Hospitality REIT Inc
NYSE:APLE
|
US |
|
B
|
Baxter International Inc
BMV:BAX
|
US |
|
Schrodinger Inc
NASDAQ:SDGR
|
US |
|
Agronomics Ltd
LSE:ANIC
|
IM |
Wall St Price Targets
C68 Price Targets Summary
Crescent Biopharma Inc
Crescent Biopharma Inc
Wall Street analysts forecast C68 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for C68 is 16.79 EUR with a low forecast of 12.4 EUR and a high forecast of 20.51 EUR.
Lowest Forecast
Price Target
12.4
EUR
19% Downside
Average Forecast
Price Target
16.79
EUR
9% Upside
Highest Forecast
Price Target
20.51
EUR
33% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is C68's stock price target?
Price Target
16.79
EUR
16.79
EUR
According to Wall Street analysts, the average 1-year price target for C68 is 16.79 EUR with a low forecast of 12.4 EUR and a high forecast of 20.51 EUR.
What is the Revenue forecast for Crescent Biopharma Inc?
Projected CAGR
81%
81%
Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 8 years is 81%.
